About Pasithea
Pasithea is a company based in Miami Beach (United States) founded in 2020 by Lawrence Steinman. It operates as a HealthTech. Pasithea has raised $1.46 million across 3 funding rounds. The company has 4 employees as of December 31, 2024. Pasithea has completed 2 acquisitions, including Allomek Therapeutics and Alpha-5 Integrin. Pasithea offers products and services including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy. Pasithea operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Miami Beach, United States
- Employees 4 as on 31 Dec, 2024
- Founders Lawrence Steinman
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pasithea Therapeutics Corp.
-
Annual Revenue
Not available
-
Net Profit
-$13.9 M (USD)12.89as on Dec 31, 2024
-
EBITDA
-$13.6 M (USD)11.28as on Dec 31, 2024
-
Total Equity Funding
$1.46 M (USD)
in 3 rounds
-
Latest Funding Round
$30.4 M (USD), Post-IPO
Nov 24, 2021
-
Investors
Not available
-
Employee Count
4
as on Dec 31, 2024
-
Investments & Acquisitions
Allomek Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pasithea
Pasithea is a publicly listed company on the NASDAQ with ticker symbol KTTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pasithea
Pasithea offers a comprehensive portfolio of products and services, including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy.
Therapy for Neurofibromatosis Type 1 is being developed.
Therapy for ALS is researched for muscle control loss.
Therapy for Multiple Sclerosis is developed for neurodegenerative issues.
Therapy for schizophrenia is explored for psychiatric treatment needs.
Funding Insights of Pasithea
Pasithea has successfully raised a total of $1.46M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.4 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Pasithea
Pasithea has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Allomek Therapeutics and Alpha-5 Integrin.
Investment portfolio details for Pasithea
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Targeted small molecule therapeutics for cancer are developed.
|
Locked | Locked | 2010 | Locked | |
|
Monoclonal antibodies are developed for treating neurological disorders.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Pasithea
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Pasithea
Detailed financials for Pasithea
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pasithea Comparisons
Peer comparison for Pasithea
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pasithea
Pasithea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Detailed competitors of Pasithea
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pasithea
Complete news archive for Pasithea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pasithea
Pasithea was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Pasithea is headquartered in Miami Beach, United States. It is registered at Miami Beach, Florida, United States.
Tiago Reis Marques is the current CEO of Pasithea.
Pasithea is a funded company, having raised a total of $1.46M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pasithea is 4.
Pasithea, a biotechnology company, is engaged in the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company is dedicated to creating therapeutics for conditions such as Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and schizophrenia. Research efforts are concentrated on addressing unmet medical needs in these areas, targeting both benign and cancerous tumors, neurodegenerative diseases, and psychiatric illnesses. Solutions are being developed to improve patient outcomes across these critical health sectors.
Pasithea's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Pasithea offers Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy.
Yes, Pasithea is publicly traded on NASDAQ under the ticker symbol KTTA.
Pasithea has made 2 acquisitions, including Allomek Therapeutics, and Alpha-5 Integrin.
The ticker symbol of Pasithea is KTTA on NASDAQ.